Clinical Trial Update: Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating safety and immunogenicity of three formulations of Takeda's tetravalent dengue vaccine candidate (TDV).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• TDV (tetravalent dengue vaccine candidate) (tetravalent dengue vaccine)

Snippet

Sponsor: Takeda | Conditions: Dengue Fever | Phase 2 | Status: COMPLETED | Results posted: 2016-06-29